PepJunkie Home of the Peptonauts
More

Peptide Atlas · Peptide

Pemvidutide

Pemvidutide is a GLP-1 and glucagon dual receptor agonist; in a 12-week randomized trial in 94 people with metabolic dysfunction-associated steatotic liver disease, weekly injections cut liver fat by 46.6% to 68.5% from baseline against 4.4% on placebo.

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 1 citation resolves to their original source. · 0 posts naming it, 0 members counted once each.

No discussion names it yet. When a post on the forum does, the thread appears here with its counts.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.